James F. Trotter

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Donor Morbidity After Living Donation for Liver Transplantation

Rafik M. Ghobrial, Chris E. Freise, James F. Trotter et al. · Gastroenterology · 2008 · 438 citations · Full text

Medicine, Surgery, Hepatology +15

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mary E. Rinella, Manal F. Abdelmalek et al. · The Lancet · 2018 · 409 citations

Medicine, Pathology, Pharmacology +17

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy†

Gregory T. Everson, James F. Trotter, Lisa Forman et al. · Hepatology · 2005 · 358 citations

Medicine, Infectious Diseases, Internal Medicine +16